Pfizer has upped the ante in the increasingly competitive market for pneumococcal vaccines with mid-stage clinical data for a ...

Pfizer Inc. PFE on Wednesday reported positive Phase 2 data for its investigational 25-valent pneumococcal conjugate vaccine ...

Pfizer Inc. said a new version of its bestselling Prevnar vaccine may provide infants with better protection against common strains of pneumonia than currently available immunizations.

New 25-strain Prevnar candidate moves into final-stage testing after strong infant trial results against severe pneumonia strain.

Pfizer said on Wednesday its experimental pneumococcal vaccine showed significantly stronger immune response than its current shot, including up to 15-fold ​higher antibody levels against a key strain ...

India's patent office has granted Pfizer a patent on its pneumococcal conjugate vaccine (PCV), known as Prevnar 13, after Doctors Without Borders (MSF) challenged the patent’s claims. The decision ...

Pfizer advances pivotal paediatric pneumococcal vaccine programme following strong positive phase 2 results: New York Thursday, May 21, 2026, 10:00 Hrs [IST] Pfizer Inc. announced ...

Earlier in May 2026, Pfizer reported positive Phase 2 results for its investigational 25‑valent pneumococcal conjugate ...

(PFE) is running a late-stage trial to test a new pneumococcal vaccine in healthy infants. The official title describes a Phase 3, randomized, double-blind study that compares a multivalent ...

Bengaluru: Pfizer said on Wednesday its experimental pneumococcal vaccine showed ​significantly stronger immune response ...

Pfizer's 25vPnC pneumococcal vaccine shows up to 15-fold higher antibody levels in infants, advancing to late-stage trials and potentially covering 90% of strains in young children ...